Literature DB >> 29142466

Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia.

Jiaxiong Tan1, Shaohua Chen1, Yuhong Lu1, Danlin Yao1, Ling Xu1, Yikai Zhang1, Lijian Yang1, Jie Chen1, Jing Lai1, Zhi Yu1, Kanger Zhu1, Yangqiu Li1,2,3.   

Abstract

OBJECTIVE: To investigate the association between the T cell inhibitory receptor programmed death 1 (PD-1) and T cell exhaustion status in T cells from patients with de novo acute myeloid leukemia (AML) and AML in complete remission (CR).
METHODS: Surface expression of PD-1 and the exhaustion and immunosenescence markers CD244 and CD57 on CD3+, CD4+ and CD8+ T cells from peripheral blood samples from 20 newly diagnosed, untreated AML patients and 10 cases with AML in CR was analyzed by flow cytometry. Twenty-three healthy individuals served as control.
RESULTS: A significantly higher percentage of PD-1+ cells were found for CD3+ T cells in the de novo AML group compared with healthy controls. In addition, an increased level of PD-1+CD8+ T cells, but not PD-1+CD4+, was found for CD3+ T cells in the de novo AML and AML-CR samples. A higher percentage of CD244+CD4+, CD244+CD8+, CD57+CD4+ and CD57+CD8+ T cells was found in CD3+ T cells in samples from those with de novo AML compared with those from healthy controls. Strong increased PD-1+CD244+ and PD-1+CD57+ co-expression was found for CD4+ and CD8+ T cells in the de novo AML group compared with healthy controls.
CONCLUSIONS: We characterized the major T cell defects, including co-expression of PD-1 and CD244, CD57-exhausted T cells in patients with de novo AML, and found a particular influence on CD8+ T cells, suggesting a poor anti-leukemia immune response in these patients.

Entities:  

Keywords:  Acute myeloid leukemia; PD-1; T cell exhaustion

Year:  2017        PMID: 29142466      PMCID: PMC5677131          DOI: 10.21147/j.issn.1000-9604.2017.05.11

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  34 in total

1.  Comment on "Molecular basis of the dual functions of 2B4 (CD244)".

Authors:  Dorothy Yuan
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

2.  Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia.

Authors:  D Serrano; J Monteiro; S L Allen; J Kolitz; P Schulman; S M Lichtman; A Buchbinder; V P Vinciguerra; N Chiorazzi; P K Gregersen
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

Review 3.  Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.

Authors:  D C Choi; D Tremblay; C Iancu-Rubin; J Mascarenhas
Journal:  Ann Hematol       Date:  2017-01-06       Impact factor: 3.673

4.  Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment.

Authors:  L E Van den Hove; P Vandenberghe; S W Van Gool; J L Ceuppens; H Demuynck; G E Verhoef; M A Boogaerts
Journal:  Leuk Res       Date:  1998-02       Impact factor: 3.156

5.  Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis.

Authors:  Joerg Uwe Schmohl; Tina Nuebling; Julia Wild; Tanja Kroell; Lothar Kanz; Helmut Rainer Salih; Helga Schmetzer
Journal:  Eur J Haematol       Date:  2016-06-05       Impact factor: 2.997

6.  Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.

Authors:  C Krupka; P Kufer; R Kischel; G Zugmaier; F S Lichtenegger; T Köhnke; B Vick; I Jeremias; K H Metzeler; T Altmann; S Schneider; M Fiegl; K Spiekermann; P A Bauerle; W Hiddemann; G Riethmüller; M Subklewe
Journal:  Leukemia       Date:  2015-08-04       Impact factor: 11.528

7.  Upregulated TCRζ improves cytokine secretion in T cells from patients with AML.

Authors:  Shaohua Chen; Xianfeng Zha; Li Shi; Lingling Zhou; Lijian Yang; Bo Li; Xiuli Wu; Jun Zhong; Tao Zhang; Yuhong Lu; Kanger Zhu; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2015-06-18       Impact factor: 17.388

8.  Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia.

Authors:  Zhenyi Jin; Qiang Luo; Shuai Lu; Xinyu Wang; Zifan He; Jing Lai; Shaohua Chen; Lijian Yang; Xiuli Wu; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2016-11-18       Impact factor: 17.388

Review 9.  The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.

Authors:  Li Shi; Shaohua Chen; Lijian Yang; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2013-09-30       Impact factor: 17.388

10.  Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia.

Authors:  Lei Qin; Donye Dominguez; Siqi Chen; Jie Fan; Alan Long; Minghui Zhang; Deyu Fang; Yi Zhang; Timothy M Kuzel; Bin Zhang
Journal:  Oncotarget       Date:  2016-09-20
View more
  19 in total

Review 1.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

2.  Lower T cell inhibitory receptor level in mononuclear cells from cord blood compared with peripheral blood.

Authors:  Ying Lin; Jinrong Lin; Jingying Huang; Youchun Chen; Jiaxiong Tan; Yangqiu Li; Shaohua Chen
Journal:  Stem Cell Investig       Date:  2019-10-21

3.  PD1 expression on bone marrow T-cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy.

Authors:  Noha Bassiouny; Nour El-Hoda; Ibtesam M Khalifa; Sara Ibrahim; Lamyaa Salem; Layla Annaka
Journal:  EJHaem       Date:  2020-05-26

4.  Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens.

Authors:  Mengjia Song; Xinfeng Chen; Liping Wang; Yi Zhang
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

Review 5.  Immune escape and immunotherapy of acute myeloid leukemia.

Authors:  Luca Vago; Ivana Gojo
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

6.  p16INK4a Regulates Cellular Senescence in PD-1-Expressing Human T Cells.

Authors:  Valérie Janelle; Mathieu Neault; Marie-Ève Lebel; Dave Maurice De Sousa; Salix Boulet; Ludovic Durrieu; Cédric Carli; Chloé Muzac; Sébastien Lemieux; Nathalie Labrecque; Heather J Melichar; Frédérick A Mallette; Jean-Sébastien Delisle
Journal:  Front Immunol       Date:  2021-08-09       Impact factor: 7.561

7.  Memory T cells skew toward terminal differentiation in the CD8+ T cell population in patients with acute myeloid leukemia.

Authors:  Ling Xu; Danlin Yao; Jiaxiong Tan; Zifan He; Zhi Yu; Jie Chen; Gengxin Luo; Chunli Wang; Fenfang Zhou; Xianfeng Zha; Shaohua Chen; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2018-07-09       Impact factor: 17.388

Review 8.  The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment.

Authors:  Laura Agresta; Kasper H N Hoebe; Edith M Janssen
Journal:  Front Immunol       Date:  2018-11-28       Impact factor: 7.561

Review 9.  Can Dendritic Cell Vaccination Prevent Leukemia Relapse?

Authors:  Liam J O'Brien; Camille Guillerey; Kristen J Radford
Journal:  Cancers (Basel)       Date:  2019-06-22       Impact factor: 6.575

10.  Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.

Authors:  Adam J Lamble; Yoko Kosaka; Ted Laderas; Allie Maffit; Andy Kaempf; Lauren K Brady; Weiwei Wang; Nicola Long; Jennifer N Saultz; Motomi Mori; David Soong; Clare V LeFave; Fei Huang; Homer Adams; Marc M Loriaux; Cristina E Tognon; Pierrette Lo; Jeffrey W Tyner; Guang Fan; Shannon K McWeeney; Brian J Druker; Evan F Lind
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.